Company: PRTA
Filing Date: 2025-03-28
Form Type: DEF 14A
Source: 0001559053-25-000017
Chunk: 98

Company: PROTHENA CORP PUBLIC LTD CO
Filing Date: 2025-03-28
Form: DEF 14A
Chunk 98
---
0 to 2021. In fiscal year 2023, our net income decreased to $( 147,028,000) , while the compensation actually paid for Dr. Kinney and for the other named executive officers decreased to $( 3,218,100) and $( 1,225,533), respectiv ely, primarily due to a decrease in our share price year-over-year . In fiscal year 2024, our net income increased to $( 122,310,000) , while the compensation actually paid for Dr. Kinney and for the other named executive officers increased to $( 1,707,034) and $( 204,492), respectively, primarily due to a smaller decrease in our share price year-over-year.

| 58 |     | 2025 PROXY STATEMENT |

TABLE OF CONTENTS

#### PAY VERSUS PERFORMANCE
| Performance Measures Used to Link Company Performance and Compensation Actually Paid to the Named Executive Officers |

As noted above, as is the case with many companies in the biotechnology industry, the Company relies less on financial performance goals as compared to non-financial strategic and operational goals. Below is a list of performance measures, which in the Company’s assessment represent the most important performance measures used by the Company to link compensation actually paid to the named executive officers for 2024. Please see the Compensation Discussion and Analysis for further information regarding how each of these measures is used in the Company’s executive compensation program. • Share Price • Progress R&D Portfolioto Achieve Primary 2024 Milestones ◦ For Birtamimab, reach decision re expansion of total enrollment in the AFFIRM-AL clinical trial; achieve an enrollment goal for the AFFIRM-AL clinical trial; execute engagement plan to support enrollment.

◦ For PRX012, complete Phase 1 clinical trial through a specified cohort; execute communication plan to support positioning. ◦ For PRX019, obtain BMS option exercise and initiate Phase 1 clinical trial. ◦ For novel platform, reach development decision based on in vivo results; initiate additional activities based on such results. • Meet Cash Burn Guidance Range and Optimize Shareholder Base ◦ Meet publicly-disclosed cash burn guidance range. ◦ Optimize shareholder base by: retaining four of top six institutional investors; galvanizing at least one institutional investor (existing or new) to take a > 5% ownership stake; or galvanizing at least five institutional investors (existing or new) to take a > 1%